Lenalidomide and Obinutuzumab for Previously Untreated CLL
Status:
Withdrawn
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is phase 1/2 study for patients with CLL or (SLL) who have not been previously treated.
This study will evaluate whether obinutuzumab and lenalidomide is safe and tolerable in this
setting and induce complete clinical responses.